USPTO serial 97867321
OPENPICHIA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 29, 2025
- Examiner
- CORWIN, KEVIN SCOTT
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with OPENPICHIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Clifford D. Hyra
Clifford D. Hyra Fresh IP PLC11710 Plaza America Drive Suite 2000Reston, VA 20190United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances, namely, pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Pharmaceutical preparations and substances, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals, and preparations in the nature of medicated wheat-free and gluten-free pasta, crackers for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Medical preparations and substances, namely, fungal preparations in the nature of fungal medications for medical purposes, probiotic preparations for medical use, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Veterinary preparations and substances, namely, fungal preparations in the nature of fungal medications for veterinary purposes; Veterinary preparations in the nature of veterinary pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Biologicals preparations for medical and veterinary use, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Diagnostic and therapeutic preparations for pharmaceutical, medical and veterinary purposes, namely, diagnostic preparations for veterinary and medical use, pharmaceutical preparations and biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Cultures for pharmaceutical, medical and veterinary purposes, namely, diagnostic media for fungal cultures and cultures of microorganisms, all for medical or veterinary purposes; Preparations and substances for use in drug discovery, namely, sterilizing preparations, growth media preparations in the nature of cell growth media for growing cells for medical and veterinary purposes, and reagents and media for medical and veterinary diagnostic purposes, namely, such media and reagents serving as inoculate, clinical medical reagents, and diagnostic reagents | ACTIVE | — |
| 042 | Science and technology services, namely, scientific and technological research in the field of pharmaceuticals, medical science, biotechnology, the food and animal feed industries, veterinary science, manufacturing of biological preparations, and in the field of industrial biotechnology; Natural science services, namely, scientific research and medical research in the fields of bacteriological, fungal, chemical, bio-technical and pharmacological research services; Clinical research, namely, scientific research in the nature of conducting clinical trials for others; medical laboratories; conducting early evaluations in the field of new pharmaceuticals; Consultancy relating to pharmaceutical research and development; Drug discovery services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 23, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 23, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 23, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 29, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 29, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 11, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 11, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 5, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 19, 2024 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Dec 13, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 30, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Aug 30, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Aug 30, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 30, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 31, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 31, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 31, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 5, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 5, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 5, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 14, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 12, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 25, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 4, 2023 | NWAP | NEW APPLICATION ENTERED | — |